‘Until and unless there are substantive and substantiated charges we remain confident that the company is strong and well placed to prosper,’ says star fund manager of Jupiter European Opportunities.
Johnnie Walker whisky to Guinness drinks giant has its 'best years ahead of it', according to Nick Train, star fund manager of Finsbury Growth & Income.
High-yielding renewable energy fund looks to catch some extra rays with a fresh wave of solar investments and extension of the life of its existing assets.
An Australian fund manager is attempting to launch the first investment company of 2019 with the flotation of US Solar Fund which would aim to deliver a 5.5% yield once fully invested.
(Update) Cash levels aren't high enough in open-ended property funds to deal with the spike in withdrawals that could be sparked by Brexit developments, warns ratings agency.
UK shares are trading at their cheapest valuation since the First World War when compared to government bonds. With a no-deal Brexit receding, now is the time to buy, say managers of JPMorgan Claverhouse.
The £850 million UK equity income trust managed by Alastair Mundy is considering a ban on ‘inherently unethical’ investments such as tobacco stocks.
Bristol-Myers Squibb’s record takeover of Celgene reassures BB Healthcare’s Paul Major that a revival of pharmaceutical M&A is on the cards, even if it typifies the sector’s current extreme volatility.
Red-hot, listed life sciences fund has its eye on Gyroscope Therapeutics' new trials as it hopes to make up for the more volatile performance of some investments such as Nightstar Therapeutics.
Amid extreme Brexit uncertainty it is encouraging to see UK smaller companies specialist Aberforth Partners concluding that long-term wealth creation from small-caps is unlikely to be affected.